Cited by 136Lipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.

Pitavastatin: Efficacy and Safety Profiles of A Novel Synthetic HMG‐CoA Reductase Inhibitor

Kajinami, Kouji, Takekoshi, Noboru, Saito, Yasushi·2003·Cardiovascular Drug Reviews

DOI 10.1111/j.1527-3466.2003.tb00116.x

Open this paper in CoChat — free account

Abstract

The use of 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase inhibitors, statins, has been shown to reduce major cardiovascular events in both primary and secondary prevention, and statins became one of the most widely prescribed classes of drugs throughout the world. Previously, statins have been well tolerated and have shown favorable safety profiles. However, the voluntary withdrawal of cerivastatin from the market because of a disproportionate number of reports of rhabdomyolysis‐associated deaths drew attention to the pharmacokinetic profile of statins, which may possibly have been related to serious drug‐drug interactions. Pitavastatin (NK‐104, previously called itavastatin or nisvastatin, Kowa Company Ltd., Tokyo) is a novel, fully synthetic statin, which has a potent cholesterol‐lowering action. The short‐term and long‐term lipid‐modifying effects of pitavastatin have already been investigated in subjects with primary hypercholesterolemia, heterozygous familial hypercholesterolemia, hypertriglyceridemia, and type‐2 diabetes mellitus accompanied by hyperlipidemia. Within the range of daily doses from 1 to 4 mg, the efficacy of pitavastatin as a lipid‐lowering drug seems to be similar, or potentially superior, to that of atorvastatin. According to the results of pharmacokinetic studies, pitavastatin showed favorable and promising safety profile; it was only slightly metabolized by the cytochrome P450 (CYP) system, its lactone form had no inhibitory effects on the CYP3A4‐mediated metabolism of concomitantly administered drugs; P‐glycoprotein‐mediated transport did not play a major role in its disposition, and pitavastatin did not inhibit P‐glycoprotein activity. It could be concluded that pitavastatin could provide a new and potentially better thera‐peutic choice for lipid‐modifying therapy than do the currently available statins. The ef‐ficacy and safety of higher dose treatment, as well as its long‐term effects in the pre‐vention of coronary artery disease, should be further investigated.

Integrity signals

Registry

Crossref · 10.1111/j.1527-3466.2003.tb00116.x

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Stimulation of Bone Formation in Vitro and in Rodents by Statins
Mundy, G. R., Garrett, R., Harris, S., Chan, J., Chen, D., Rossini, G., Boyce, B. F., Zhao, M., & Gutierrez, G. (1999) · Science · doi:10.1126/science.286.5446.1946 · Cited by 1,776
Statin-associated myopathy
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
New insights into the pharmacodynamic and pharmacokinetic properties of statins
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00045-5 · Cited by 796
Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors: Similarities and Differences
Lennernäs, H., & Fager, G. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732050-00005 · Cited by 527
Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization
Prueksaritanont, T., Subramanian, R., Fang, X., Ma, B., Qiu, Y., Lin, J. H., Pearson, P. G., & Baillie, T. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.5.505 · Cited by 344
Gemfibrozil greatly increases plasma concentrations of cerivastatin
Backman, J. T. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.128469 · Cited by 337
Effect of itraconazole on the pharmacokinetics of atorvastatin*
Kantola, T., Kivistö, K. T., & Neuvonen, P. J. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90023-6 · Cited by 300
Mechanistic Studies on Metabolic Interactions between Gemfibrozil and Statins
Prueksaritanont, T., Zhao, J. J., Ma, B., Roadcap, B. A., Tang, C., Qiu, Y., Liu, L., Lin, J. H., Pearson, P. G., & Baillie, T. A. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.1042 · Cited by 282
Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid*
Kantola, T., Kivistö, K. T., & Neuvonen, P. J. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90034-0 · Cited by 275
Plasma concentrations of active simvastatin acid are increased by gemfibrozil
Backman, J. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.108507 · Cited by 264
Lactonization Is the Critical First Step in the Disposition of the 3-Hydroxy-3-Methylglutaryl-Coa Reductase Inhibitor Atorvastatin
Jacobsen, W., Kuhn, B., Soldner, A., Kirchner, G. I., Sewing, K.-F., Kollman, P. A., Benet, L. Z., & Christians, U. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15086-6 · Cited by 236
Metabolism and Drug Interactions of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Transplant Patients
Christians, U., Jacobsen, W., & Floren, L. C. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00016-3 · Cited by 222
HMG‐CoA reductase inhibitors and P‐glycoprotein modulation
Bogman, K., Peyer, A., Török, M., Küsters, E., & Drewe, J. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703920 · Cited by 194
Pitavastatin Enhanced BMP-2 and Osteocalcin Expression by Inhibition of Rho-Associated Kinase in Human Osteoblasts
Ohnaka, K., Shimoda, S., Nawata, H., Shimokawa, H., Kaibuchi, K., Iwamoto, Y., & Takayanagi, R. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5597 · Cited by 191
Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate
Kyrklund, C., Backman, J. T., Kivistö, K. T., Neuvonen, M., Laitila, J., & Neuvonen, P. J. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115542 · Cited by 191
Gemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver Microsomes
Wang, J.-S., Neuvonen, M., Wen, X., Backman, J. T., & Neuvonen, P. J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1352 · Cited by 189
Atorvastatin Coadministration May Increase Digoxin Concentrations by Inhibition of Intestinal P-Glycoprotein-Mediated Secretion
Boyd, R. A., Stern, R. H., Stewart, B. H., Wu, X., Reyner, E. L., Zegarac, E. A., Randinitis, E. J., & Whitfield, L. R. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/00912700022008612 · Cited by 179
HMG-CoA Reductase Inhibitors (Statins) Characterized as Direct Inhibitors of P-Glycoprotein
Wang, E., Casciano, C. N., Clement, R. P., & Johnson, W. W. (2001) · Pharmaceutical Research · doi:10.1023/a:1011036428972 · Cited by 177
Drug Interactions with Calcium Channel Blockers: Possible Involvement of Metabolite-Intermediate Complexation with CYP3A
Ma, B., Prueksaritanont, T., & Lin, J. H. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15118-5 · Cited by 177
In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors
Transon, C., Leemann, T., & Dayer, P. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050094 · Cited by 173
The Effect of Statins on mRNA Levels of Genes Related to Inflammation, Coagulation, and Vascular Constriction in HUVEC.
Morikawa, S., Takabe, W., Mataki, C., Kanke, T., Itoh, T., Wada, Y., Izumi, A., Saitō, Y., Hamakubo, T., & Kodama, T. (2002) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.9.178 · Cited by 167
The 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Fluvastatin: Effect on Human Cytochrome P-450 and Implications for Metabolic Drug Interactions
Fischer, V., Johanson, L., Heitz, F., Tullman, R. H., Graham, E., Baldeck, J. P., & Robinson, W. T. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14919-7 · Cited by 148
Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen, X., Wang, J. S., Backman, J. T., Kivistö, K. T., & Neuvonen, P. J. (2001) · PubMed · Cited by 139
Clinical Pharmacokinetics of Cerivastatin
ck, W. M. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039020-00002 · Cited by 122
A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia
Saitō, Y., Yamada, N., Teramoto, T., Itakura, H., Yoshiya, H. A. T. A., Nakaya, N., Mabuchi, H., Tushima, M., Sasaki, J., & Ogawa, N. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00712-2 · Cited by 114
Biotransformation of pravastatin sodium in humans.
Everett, D. W., Chando, T. J., DiDonato, G. C., Singhvi, S. M., Pan, H., & Weinstein, S. H. (1991) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08889-0 · Cited by 112
Erythromycin Coadministration Increases Plasma Atorvastatin Concentrations
Siedlik, P. H., Olson, S. C., Yang, B., & Stern, R. H. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/009127009903900510 · Cited by 110
In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin*
Transon, C., Leemann, T., Vogt, N., & Dayer, P. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90054-3 · Cited by 105
Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy
POGSON, G. W., Kindred, L. H., & Carper, B. G. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00034-x · Cited by 105
Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Aoki, T., Nishimura, H., Nakagawa, S., Kojima, J., Suzuki, H., Tamaki, T., Wada, Y., Yokoo, N., Sato, F., KIMATA, H., et al. (1997) · PubMed · Cited by 104
Self-citation
Pharmacology of 3‐Hydroxy‐3‐Methylglutaryl‐Coenzyme A Reductase Inhibitors (Statins), Including Rosuvastatin and Pitavastatin
Igel, M., Sudhop, T., & von Bergmann, K. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127002401102731 · Cited by 100
Safety considerations for statins
Bolego, C., Baetta, R., Bellosta, S., Corsini, A., & Paoletti, R. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200212000-00007 · Cited by 98
Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization
Fujino, H., Yamada, I., Shimada, S., Yoneda, M., & Kojima, J. (2003) · Xenobiotica · doi:10.1080/0049825021000017957 · Cited by 96
Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors
Suzuki, M., Iwasaki, H., Fujikawa, Y., Kitahara, M., Sakashita, M., & Sakoda, R. (2001) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00198-5 · Cited by 88
NK-104: a novel synthetic HMG-CoA reductase inhibitor
Kajinami, K., Mabuchi, H., & Saito, Y. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.11.2653 · Cited by 85
Self-citation
Relative Induction of mRNA for HMG CoA Reductase and LDL Receptor by Five Different HMG-CoA Reductase Inhibitors in Cultured Human Cells
Morikawa, S., Umetani, M., Nakagawa, S., Yamazaki, H., Suganami, H., Inoue, K., Kitahara, M., Hamakubo, T., Kodama, T., & Saitō, Y. (2000) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat1994.7.138 · Cited by 76
Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia
Noji, Y., Higashikata, T., Inazu, A., Nohara, A., Ueda, K., Miyamoto, S., Kajinami, K., Takegoshi, T., Koizumi, J., & Mabuchi, H. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00765-1 · Cited by 74
Self-citation
Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia
Kajinami, K., Koizumi, J., Ueda, K., Miyamoto, S., Takegoshi, T., & Mabuchi, H. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00656-6 · Cited by 68
Self-citation
Clinical Efficacy of Pitavastatin, a New 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitor, in Patients with Hyperlipidemia
Saitō, Y., Yamada, N., Teramoto, T., Itakura, H., Yoshiya, H. A. T. A., Nakaya, N., Mabuchi, H., Tushima, M., Sasaki, J., Goto, Y., et al. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1299888 · Cited by 66
Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs
Suzuki, H., Aoki, T., Tamaki, T., Sato, F., Kitahara, M., & Saitō, Y. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00146-x · Cited by 65
Simvastatin and lovastatin, but not pravastatin, interact with MDR1
Sakaeda, T., Takara, K., Kakumoto, M., Ohmoto, N., Nakamura, T., Iwaki, K., Tanigawara, Y., & Okumura, K. (2002) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357021778493 · Cited by 52
Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reductase (1) : Absorption, Distribution, Metabolism and Excretion in Rats
KIMATA, H., Fujino, H., Koide, T., Yamada, Y. M. A., Tsunenari, Y., & Yanagawa, Y. (1998) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.13.484 · Cited by 51
Plaque-Stabilizing Effect of Pitavastatin in Watanabe Heritable Hyperlipidemic(WHHL) Rabbits.
Suzuki, H., Hideyuki, K., Sato, F., Yonemitsu, Y., Nakashima, Y., & Sueishi, K. (2003) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.10.109 · Cited by 47
Quantitative Distinctions of Active Site Molecular Recognition by P-Glycoprotein and Cytochrome P450 3A4
Wang, E., Lew, K., Barecki-Roach, M., Casciano, C. N., Clement, R. P., & Johnson, W. W. (2001) · Chemical Research in Toxicology · doi:10.1021/tx010125x · Cited by 47
HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes
Sone, H., Takahashi, A., Shimano, H., Ishibashi, S., Yoshino, G., Morisaki, N., Saitō, Y., Kawazu, S., Teramoto, T., Fujita, T., et al. (2002) · Life Sciences · doi:10.1016/s0024-3205(02)02038-6 · Cited by 45
Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reductase. (4). Interspecies Variation in Laboratory Animals and Humans.
Fujino, H., Kojima, J., Yamada, Y., Kanda, H., & KIMATA, H. (1999) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.14.79 · Cited by 37
Inhibition of Migration and Proliferation of Rat Vascular Smooth Muscle Cells by a New HMG-CoA Reductase Inhibitor, Pitavastatin
Kohno, M., Shinomiya, K., Abe, S., Noma, T., Kondô, I., Oshita, A., Takeuchi, H., TAKAGI, Y., Yukiiri, K., Mizushige, K., et al. (2002) · Hypertension Research · doi:10.1291/hypres.25.279 · Cited by 35
Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reductase. (5). In Vitro Metabolism and Plasma Protein Binding in Animals and Human.
Fujino, H., Yamada, I., Kojima, J., Hirano, M., Matsumoto, H., & Yoneda, M. (1999) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.14.415 · Cited by 35
NK-104, a Newly Developed HMG-CoA Reductase Inhibitor, Suppresses Neointimal Thickening by Inhibiting Smooth Muscle Cell Growth and Fibronectin Production in Balloon-Injured Rabbit Carotid Artery
Kitahara, M., Kanaki, T., Toyoda, K., Miyakoshi, C., Tanaka, S., Tamaki, T., & Saitō, Y. (1998) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.77.117 · Cited by 35
NK‐104, a 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells
Takemoto, M., Kitahara, M., Yokote, K., Asaumi, S., Take, A., Saitō, Y., & Mori, S. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704046 · Cited by 28
Metabolic Fate of Pitavastatin, a New Inhibitor of HMG-CoA Reductase—Effect of cMOAT Deficiency on Hepatobiliary Excretion in Rats and of mdr 1a/b Gene Disruption on Tissue Distribution in Mice
Fujino, H., Yamada, I., Shimada, S., & Kojima, J. (2002) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.17.449 · Cited by 27
Pitavastatin Inhibits Vascular Smooth Muscle Cell Proliferation by Inactivating Extracellular Signal-Regulated Kinases 1/2.
Yamakawa, T., Tanaka, S., Kamei, J., Kadonosono, K., & Okuda, K. (2003) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.10.37 · Cited by 27
Simultaneous determination of taxol and its metabolites in microsomal samples by a simple thin-layer chromatography radioactivity assay — inhibitory effect of NK-104, a new inhibitor of HMG-CoA reductase
Fujino, H., Yamada, I., Shimada, S., & Yoneda, M. (2001) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(01)00141-4 · Cited by 25
First systematic chiral syntheses of two pairs of enantiomers with 3,5-dihydroxyheptenoic acid chain, associated with a potent synthetic statin NK-104
Suzuki, M., Yanagawa, Y., Iwasaki, H., Kanda, H., Yanagihara, K., Matsumoto, H., Ohara, Y., Yazaki, Y., & Sakoda, R. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00519-3 · Cited by 23
INTERACTION BETWEEN FIBRATES AND STATINS - METABOLIC INTERACTIONS WITH GEMFIBROZIL
Fujino, H., Yamada, I., Shimada, S., Hirano, M., Tsunenari, Y., & Kojima, J. (2003) · Drug metabolism and drug interactions · doi:10.1515/dmdi.2003.19.3.161 · Cited by 23
NK-104, a potent new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, enhances posttranslational catabolism of apolipoprotein B-100 and inhibits secretion of apolipoprotein B-100 and triacylglycerols from HepG2 cells
Yanagita, T., Hara, E., Yotsumoto, H., Rahman, S. M., Han, S.-Y., Cha, J.-Y., & Yamamoto, K. (1999) · Current Therapeutic Research · doi:10.1016/s0011-393x(99)80021-6 · Cited by 20
Interaction between Several Medicines and Statins
Fujino, H., Saito, T., Tsunenari, Y., & Kojima, J. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1297087 · Cited by 20
Triglyceride-lowering effect of pitvastatin in a rat model of postprandial lipemia
Aoki, T., Yoshinaka, Y., Yamazaki, H., Suzuki, H., Tamaki, T., Sato, F., Kitahara, M., & Saitō, Y. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01547-9 · Cited by 19
NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells
Ooyen, C., Zecca, A., Bersino, A. M., & Catapano, A. L. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00018-0 · Cited by 17
Effect of Biliary Excretion on the Pharmacokinetics of Pitavastatin (NK-104) in Dogs.
Kojima, J., OHSHIMA, T., Yoneda, M., & Sawada, H. (2001) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.16.497 · Cited by 14
Synthesis of piperazine derivatives and evaluation of their antihistamine and antibradykinin effects
Choo, H. P., Chung, B., & Chung, S.-H. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00471-0 · Cited by 13
Hypolipidemic Effect of NK-104 and Other 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Guinea Pigs
Suzuki, H., Yamazaki, H., Aoki, T., Tamaki, T., Sato, F., Kitahara, M., & Saitō, Y. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1300000 · Cited by 12
Effect of NK-104, a new synthetic HMG-CoA reductase inhibitor, on triglyceride secretion and fatty acid oxidation in rat liver
Yamamoto, K., Todaka, N., Goto, H., Jayasooriya, A. P., Sakono, M., Ogawa, Y., & Fukuda, N. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00390-2 · Cited by 9
Clinical evaluation of NK-104 (itavastatin) in long-term treatment of patients with hyperlipidemia
Teramoto, T., Saito, Y., & Nakaya, N. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)80238-5 · Cited by 9
Self-citation
New Nomenclature of Human ABC Transporter Genes.
Ishikawa, T., ALLIKIMETS, R., Dean, M. C., Higgins, C. F., Ling, V. W. T., & Wain, H. (2000) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.15.8 · Cited by 7
Cholesterol-lowering Effect of NK-104, a 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Inhibitor, in Guinea Pig Model of Hyperlipidemia
Aoki, T., Yamazaki, H., Suzuki, H., Tamaki, T., Sato, F., Kitahar, M., & Saitō, Y. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1300025 · Cited by 6
Efficacy and safety of a new HMG-CoA reductase inhibitor, NK-104, in patients with hypertriglyceridemia — Randomized double-blind, cross-over placebo controlled study
Sasaki, J., Ikeda, Y., Yamamoto, K., Ageta, M., & Arakawa, K. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)80335-4 · Cited by 5
Triglyceride-lowering Effect of Pitavastatin in a Guinea Pig Model of Postprandial Lipemia
Aoki, T., Yamazaki, H., Tamaki, T., Sato, F., Kitahara, M., & Saitō, Y. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1297088 · Cited by 5

Research works printed but not linked: 6

FujinoH ShimadaS YamadaI TsunenariY HiranoM KojimaJ.Interaction between fibrates and statins. In:Abstract of 13th International conference on cytochromes P450 2003(in Czech).
Nakaya N, 2001, A Phase 1 clinical study of a novel HMG‐CoA reductase inhibitor, NK‐104 (pitavastatin). Results of single and 7‐day repeated oral administration studies in healthy adult male volunteers, J Clin Ther Med, 17, 741
Nakaya N, 2001, Efficacy and safety of NK‐104 (pitavastatin), a novel HMG‐CoA reductase inhibitor in hypercholesterolemic volunteers, J Clin Ther Med, 17, 767
Nakaya N, 2001, Pharmacokinetics of repeated Dose NK‐104 (pitavastatin), in healthy elderly and non‐elderly volunteers, J Clin Ther Med, 17, 957
Ouchi Y, 2001, Efficacy and safety of NK‐104 (pitavastatin), a new HMG‐CoA reductase inhibitor in the elderly patients with hyperlipidemia, Geriatr Med, 39, 849
Shimada Y, 1996, Partition coefficient and hepatic cell‐selectivity of HMG‐CoA Reductase inhibitors, Progr Med, 18, 957

Sorted by citations

Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,086
Natural products to drugs: natural product derived compounds in clinical trials
Butler, M. S. (2005) · Natural Product Reports · doi:10.1039/b402985m · Cited by 496
Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans
Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068056 · Cited by 444
“Pitavastatin is a highly potent inhibitor of 3-hydroxy-3methylglutaryl (HMG)-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis (Aoki et al., 1997; Kajinami et al., 2003).”
Influential
Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association
Wiggins, B. S., Saseen, J. J., Page, R. L., II, Reed, B. N., Sneed, K., Kostis, J. B., Lanfear, D. E., Virani, S. S., & Morris, P. B. (2016) · Circulation · doi:10.1161/cir.0000000000000456 · Cited by 345
DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1
Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.009290 · Cited by 302
“Pitavastatin is a highly potent inhibitor of HMG-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis (Aoki et al., 1997; Kajinami et al., 2003).”
Background

See all 136

Authors: Kajinami, K., Takekoshi, N., & Saito, Y.
Affiliations: Kanazawa Medical University (JP)
Chiba University (JP)
Corresponding author: Kajinami, Kouji
ORCID: Saito, Yasushi
Venue: Cardiovascular Drug Reviews
Publisher: Wiley
Published: 2003-09
Volume: 21
Issue: 3
Pages: 199-215
ISSN: 0897-5957 (ISSN-L)
1527-3466
DOI: 10.1111/j.1527-3466.2003.tb00116.x
OpenAlex: W2074541010
Cited by: 136
References: 77
Citations by year: 2026: 5 · 2025: 4 · 2024: 2 · 2023: 3 · 2022: 8 · 2021: 8 · 2020: 4 · 2019: 3 · 2018: 1 · 2017: 5 · 2016: 6 · 2015: 3 · 2014: 6 · 2013: 4 · 2012: 2
FWCI: 8.31
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 1010 d)
Locations: Cardiovascular Drug Reviews (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords: pitavastatin, statins, lipid-lowering therapy, hypercholesterolemia, familial hypercholesterolemia, hypertriglyceridemia, type 2 diabetes, pharmacokinetics, drug-drug interactions, cytochrome P450, P-glycoprotein, rhabdomyolysis, atorvastatin comparison, coronary heart disease prevention
MeSH terms: Animals, Arteriosclerosis, Clinical Trials as Topic, Cytochrome P-450 Enzyme System, Drug Interactions, Humans, Hypercholesterolemia, Lipoproteins, Quinolines, Hydroxymethylglutaryl-CoA Reductase Inhibitors, ATP Binding Cassette Transporter, Subfamily B, Member 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pitavastatin: Efficacy and Safety Profiles of A Novel Synthetic HMG‐CoA Reductase Inhibitor

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks